Trial of Novartis chronic heart failure drug closes early based on promising interim results

Posted On 31 Mar 2014
By :

Data Monitoring Committee (DMC) unanimously recommended early closure of the PARADIGM-HF study, indicating patients with chronic heart failure with reduced ejection fraction (HF-REF) who received LCZ696 lived longer without being hospitalized for heart failure than those who received standard care with ACE-inhibitor enalapril.

Based on the compelling efficacy and primary endpoint having been met, the trial will close early, and the results submitted to a major medical conference for presentation. Novartis will now also initiate discussions with global health authorities regarding approval for marketing.

Read the source article at Novartis

About the Author

Leave a Reply